QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform. QLS-111 lowers ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

Iantrek has reached an exciting milestone as we transition from development of our bio-interventional technologies to ...

We present a case of unilateral, secondary open-angle glaucoma due to an underlying diffuse iris melanoma. The patient was referred by his ophthalmologist with uncontrolled, elevated intraocular ...

It is implanted through the trabecular meshwork and back wall of Schlemm's canal, directly into scleral tissue. 1 In a new 36-month follow-up analysis of the company’s 2 Phase 3 pivotal clinical ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Failure of the Paul Glaucoma Implant occurred in 8% ...

Made from medical-grade titanium, iDose TR is implanted through the trabecular meshwork and back wall of Schlemm’s canal, directly into scleral tissue. Once implanted, 75 mcg of a novel, ...

Professor at the University of Nebraska Medical Center shared “All conventional approaches have focused on the trabecular meshwork and the inner canal wall. We have shown empirically and ...